Combined targeted and immunotherapy: The future of personalized medicine

Aurélien Marabelle; Christophe Caux

doi:10.1182/blood-2012-09-455105

Combined targeted and immunotherapy: The future of personalized medicine

Aurélien Marabelle, Christophe Caux

Résultats de recherche: Contribution à un journal › !!Comment/debate

7 Citations (Scopus)

Résumé

In this issue of Blood, Yang et al have demonstrated that the therapeutic activity of a targeted therapy, the tyrosine kinase inhibitor (TKI) dasatinib, unexpectedly depends on antitumor T-cell responses that are strongly potentiated by immunostimulation (agonist anti-OX40).

langue originale	Anglais
Pages (de - à)	4454-4455
Nombre de pages	2
journal	Blood
Volume	120
Numéro de publication	23
Les DOIs	https://doi.org/10.1182/blood-2012-09-455105
état	Publié - 29 nov. 2012
Modification externe	Oui

Accès au document

10.1182/blood-2012-09-455105

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{4b284ff0cae640dcbbd1275e5e97f28e,

title = "Combined targeted and immunotherapy: The future of personalized medicine",

abstract = "In this issue of Blood, Yang et al have demonstrated that the therapeutic activity of a targeted therapy, the tyrosine kinase inhibitor (TKI) dasatinib, unexpectedly depends on antitumor T-cell responses that are strongly potentiated by immunostimulation (agonist anti-OX40).",

author = "Aur{\'e}lien Marabelle and Christophe Caux",

year = "2012",

month = nov,

day = "29",

doi = "10.1182/blood-2012-09-455105",

language = "English",

volume = "120",

pages = "4454--4455",

journal = "Blood",

issn = "0006-4971",

number = "23",

}

TY - JOUR

T1 - Combined targeted and immunotherapy

T2 - The future of personalized medicine

AU - Marabelle, Aurélien

AU - Caux, Christophe

PY - 2012/11/29

Y1 - 2012/11/29

N2 - In this issue of Blood, Yang et al have demonstrated that the therapeutic activity of a targeted therapy, the tyrosine kinase inhibitor (TKI) dasatinib, unexpectedly depends on antitumor T-cell responses that are strongly potentiated by immunostimulation (agonist anti-OX40).

AB - In this issue of Blood, Yang et al have demonstrated that the therapeutic activity of a targeted therapy, the tyrosine kinase inhibitor (TKI) dasatinib, unexpectedly depends on antitumor T-cell responses that are strongly potentiated by immunostimulation (agonist anti-OX40).

UR - http://www.scopus.com/inward/record.url?scp=84870527415&partnerID=8YFLogxK

U2 - 10.1182/blood-2012-09-455105

DO - 10.1182/blood-2012-09-455105

M3 - Comment/debate

C2 - 23197581

AN - SCOPUS:84870527415

SN - 0006-4971

VL - 120

SP - 4454

EP - 4455

JO - Blood

JF - Blood

IS - 23

ER -